Aurubis AG

  • WKN: 676650
  • ISIN: DE0006766504
  • Land: Deutschland

Nachricht vom 12.06.2019 | 17:23

Aurubis: In its ordinary meeting today, the Supervisory Board unanimously released J. Schachler (CEO) from his duties, effective immediately. Furthermore, the Executive Board and Supervisory Board have passed a resolution to stop investment project FCM

Aurubis AG / Key word(s): Profit Warning/Personnel
Aurubis: In its ordinary meeting today, the Supervisory Board unanimously released J. Schachler (CEO) from his duties, effective immediately. Furthermore, the Executive Board and Supervisory Board have passed a resolution to stop investment project FCM

12-Jun-2019 / 17:23 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


In its ordinary meeting today, the Supervisory Board unanimously released Executive Board Chairman Jürgen Schachler from his duties, effective immediately.

Furthermore, the Executive Board and Supervisory Board have passed a resolution to stop investment project FCM (Future Complex Metallurgy).

Hamburg, June 12, 2019

Aurubis AG expects the current economic environment to strain the Q3 2018/19 result (previous year: op. EBT of EUR 78 million) and the full-year result (previous year: op. EBT of EUR 329 million). Furthermore, the Executive Board and Supervisory Board have passed a resolution to stop the internal investment project Future Complex Metallurgy (FCM).

The investment costs of the project that have been capitalized thus far will consequently place an additional strain of approximately EUR 30 million on the Q3 2018/19 result.

The originally planned investment amount was supposed to be EUR 320 million. EBITDA contributions amounting to EUR 80 million were expected starting in FY 2022/23. The basic engineering results indicated significantly higher investment costs. The project is thus no longer as cost-effective as originally expected.

In its ordinary meeting today, the Supervisory Board also unanimously released Executive Board Chairman Jürgen Schachler from his duties, effective immediately.

Internal growth options will be reviewed again with the objective of an integrated Aurubis AG smelter network in the future.

Contact:

Dr. Björn Carsten Frenzel
Head of Corporate Legal Affairs
E-mail: c.frenzel@aurubis.com
Phone: +49 40 78 83 30 44


12-Jun-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Anleihe im Fokus

PREOS Real Estate AG
"7,5%-Wandelanleihe - Jetzt bis 04.12.19 zeichnen!"

- Emissionsvolumen: bis zu 300 Mio. EUR
- Zeichnungsfrist: 11.19. bis 04.12.2019
- ISIN: DE 000A254NA6 / WKN: A254NA
- Börsenesegment: Börse Frankfurt, Open Market
- Stückelung: 1.000 EUR
- Zinssatz (Kupon): 7,5% p.a., jährliche Zahlung
- Laufzeit: 5 Jahre
- Endfälligkeit: 09.12.2024

Anleihe im Fokus

Deutsche Rohstoff
"Anleihe - Jetzt zeichnen!"

- Emissionsvolumen: bis zu 100 Mio. EUR
- Zeichnungsfrist: 11.11. bis 04.12.2019
- ISIN: DE000A2YN3Q8 / WKN: A2YN3Q
- Börsenesegment: Börse Frankfurt, Open Market (Quotation Board)
- Stückelung / Emissionspreis: 1.000 EUR/ 100%
- Zinssatz (Kupon): 5,25 %
- Laufzeit: 5 Jahre
- Fälligkeit: 5 Jahre / 6.12.2024 (vorbehaltliche vorzeitige Rückzahlung gemäß Anleihebedingungen)
- Zinszahlung: Angebot an Inhaber der 5,625 % Schuldverschreibung 2016/2021 (WKN A2AA05, ISIN DE000A2AA055) diese in die neue Anleihe zu tauschen
- Umtauschfrist: 11.11.2019 – 29.11.2019 (18.00 Uhr)

GBC-Fokusbox

Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

Aktueller Webcast

EQS Group AG

Conference Call zu den Neunmonatszahlen 2019

15. November 2019

Aktuelle Research-Studie

Schloss Wachenheim AG

Original-Research: Schloss Wachenheim AG (von First Berlin Equity Research GmbH): Kaufen

19. November 2019